You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
723 Metabolically reprogrammed autologous Th1/Tc1 cell therapy (RAPA-201) yields promising safety and efficacy in post-PD-(L)1 solid tumor patients without lymphodepleting host conditioning

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023176010
Dec 202342010
Jan 20243104
Feb 20243607
Mar 202430010
Apr 202442011
May 20243401
Jun 20244601
Jul 20244804
Aug 20244206
Sep 202442010
Oct 20244809
Nov 202454012
Dec 202478023
Jan 202591014
Feb 202524011
Mar 20250010
Apr 2025006
May 2025009
Jun 2025004
Total8640172